Penday is Innopulse’s German-language companion app for GLP-1 therapy — from Wegovy through Ozempic and Mounjaro to Saxenda. The guiding idea: a GLP-1 therapy is more than one injection a week. Penday accompanies every phase, from the start through everyday use to tapering off, phase-aware, neutral, and ad-free. Not a tracker that collects data, but a companion that knows what matters in each therapy phase.
Why a specialised app rather than a general tracker
Generic health apps try to cover everything: steps, sleep, calories, hydration. Penday does the opposite — one thing, done right. The product knows the pharmacokinetic profiles of all GLP-1 active ingredients, the titration schedules of the pen manufacturers, the typical side-effect courses of the first eight weeks, and the health-insurance conditions in Switzerland, Germany, and Austria. This specialisation enables functions a general app cannot deliver — from the estimated active-level curve to the structured doctor report in an MDK-suitable format. Anyone going through a GLP-1 therapy needs not another step counter but a tool that understands the specific reality of this therapy.
Injection tracker with site rotation
The core of Penday is an injection tracker that records weekday, time, dose, and injection site — with an automatic rotation suggestion. This is medically relevant: repeated injections at the same site lead to lipohypertrophy, fatty-tissue thickening in which absorption becomes unreliable. Penday’s site-rotation map follows the FITTER consensus and warns automatically as soon as the same site is used more than twice in a row. Added to this is the adherence aspect: real-world analyses show that timely use in the first weeks correlates with markedly better results. Penday’s adherence score gives the doctor’s appointment a concrete number rather than a vague impression.
Symptom log and progress dashboard
Penday offers a symptom log with over ten predefined side effects and a severity scale from one to five that detects correlations — for instance between dose increases and phases of nausea. The progress dashboard tracks weight, BMI, and measurements and makes the course comparable with the values from the STEP and SURMOUNT studies. This is more than motivation: anyone watching only the final weight misses the measurable patterns in between. Anyone who recognises the right signals early can adjust the strategy in time together with the treating physician.
AI companion with therapeutic context
Penday’s AI companion answers questions at any time — with full context on the individual therapy. Unlike a general search engine, the companion knows the medication being taken, the current dose, the therapy phase, and the course so far, and can frame questions accordingly. This is AI integration with real benefit: instead of generic answers, the companion delivers framing related to the user’s specific situation — always with the clear note that it does not replace medical advice.
Doctor report in one tap
One of the most valuable functions is the doctor report: with one tap, Penday generates a structured PDF report for the next appointment or an MDK assessment. The report summarises adherence, symptom course, and progress data in a form that is genuinely useful in the medical conversation or the reimbursement process. Especially in the DACH region, where reimbursement conditions are complex and country-specific, this structured documentation is a concrete advantage.
With health data, privacy is non-negotiable
Health data is the most sensitive data category under Article 9 GDPR, and Penday treats it accordingly. The data does not leave the EU — database and hosting run in Frankfurt am Main. Penday uses only technically necessary cookies, runs no web analytics, no ad networks, and no data-transmitting social-media plugins. The account can be fully deleted or exported as JSON at any time, each in under 30 seconds. This consistent data-protection architecture is not an add-on but a precondition for a product that works with health data — and an example of the health-tech architecture Innopulse also implements for clients.
Who Penday is made for
What the clinical studies say — and why tracking matters
GLP-1 receptor agonists work over months with measurable patterns, not overnight. The STEP-1 study showed for Wegovy a median weight loss of 14.9 percent over 68 weeks; SURMOUNT-1 for Mounjaro at the highest dose even around 20.9 percent over 72 weeks. But these median values mean that half the participants lost more and half less — there are strong responders and non-responders. Anyone who recognises the right signals early can adjust the strategy in time with the treating physician. This is exactly where Penday’s structured tracking comes in: it makes the individual course visible and comparable, rather than looking only at the final weight. Several real-world analyses also show that high adherence in the first 16 weeks correlates with markedly better results — Penday’s adherence score translates that into a concrete number for the doctor’s appointment.
DACH reimbursement, explained country by country
The reimbursement of GLP-1 medications is complex in the DACH region and differs from country to country — an area where Penday delivers concrete added value. In Switzerland, reimbursement of Wegovy via the compulsory health insurance generally requires a BMI of 35 or above with comorbidities, a prior assessment, and a re-evaluation after six months. In Germany, the lifestyle exclusion under Section 34 SGB V generally rules out Wegovy for pure weight reduction, meaning self-payer costs of around 230 to 320 euros per month. In Austria, reimbursement runs via the EKO box system with chief-physician approval. Penday’s reimbursement hub explains, for each medication-country pair, the exact conditions and application paths — and the structured doctor report provides the documentation needed in the reimbursement process and in an MDK assessment. This country-specific depth is only possible because Penday specialises in GLP-1 rather than trying to cover everything.
Phase awareness as a design principle
The central design principle that distinguishes Penday from ordinary tracking apps is phase awareness. A GLP-1 therapy does not run uniformly but in phases: the rise of the active level after the injection, the peak effect, the decline before the next dose, and over weeks the titration into higher doses with their own side-effect patterns. Penday knows these phases and adapts its guidance to them — in the rise phase, for instance, the note to keep meals mild and drink enough water, because nausea is more likely here. This phase sensitivity turns a passive logbook into an active companion that knows what matters right now. It is only possible because Penday understands the pharmacokinetics of the GLP-1 active ingredients and does not try to be a generic health tracker. Exactly this depth — one thing right rather than fifty superficially — is the design stance that characterises Penday.
Penday is aimed at people in the DACH region who are going through a GLP-1 therapy and want to accompany it consciously — neutral, ad-free, and in German. Penday does not replace medical advice; for medical questions the treating physician is the right address. Penday is a trademark of Innopulse Consulting GmbH registered with the Swiss Federal Institute of Intellectual Property and is available at penday.eu.